Serum growth differentiation factor 15 level is associated with muscle strength and lower extremity function in older patients with cardiometabolic disease.
Aged
Aged, 80 and over
Biomarkers
/ blood
Cardiovascular Diseases
/ blood
Diabetes Mellitus
/ blood
Female
Frailty
Growth Differentiation Factor 15
/ blood
Hand Strength
Humans
Lower Extremity
/ physiopathology
Male
Muscle Strength
/ physiology
Muscle, Skeletal
/ physiopathology
Sarcopenia
/ blood
Time and Motion Studies
Walking Speed
/ physiology
diabetes mellitus
growth differentiation factor 15 (GDF15)
lower extremity function
sarcopenia
Journal
Geriatrics & gerontology international
ISSN: 1447-0594
Titre abrégé: Geriatr Gerontol Int
Pays: Japan
ID NLM: 101135738
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
13
05
2020
revised:
29
07
2020
accepted:
31
07
2020
pubmed:
5
9
2020
medline:
21
10
2020
entrez:
4
9
2020
Statut:
ppublish
Résumé
Sarcopenia is a serious problem because of its poor prognosis. Growth differentiation factor 15 (GDF15) is associated with mitochondrial dysfunction, inflammation, insulin resistance and oxidative stress, which may play crucial roles for the development of sarcopenia. We aimed to examine whether serum GDF15 level is associated with muscle mass, strength and lower extremity function in older patients with cardiometabolic disease. Serum GDF15 levels were measured in 257 patients with cardiometabolic diseases (including 133 patients with diabetes) who had visited the frailty clinic, using a latex turbidimetric immunoassay. Appendicular skeletal muscle index, handgrip strength, timed-up-and-go test and gait speed were evaluated. Power, speed, balance and total scores based on the sit-to-stand test were calculated to assess lower extremity function. The highest tertile of serum GDF15 was independently associated with low handgrip strength, low gait speed, long timed-up-and-go time and scores of lower extremity function but not an appendicular skeletal muscle index in multiple logistic regression analyses after adjustment for covariates. Patients in the highest tertile of GDF15 were at the risk of having three to nine times lower grip strength, three times lower gait speed, five to six times lower mobility and five to 11 times reduction in lower extremity function as compared with those in the lowest GDF15 tertile dependent on the models. Elevated serum GDF15 level was independently associated with low muscle strength and lower extremity function in older patients with cardiometabolic disease. Serum GDF15 could be one of the biomarkers for muscle weakness and low physical performance. Geriatr Gerontol Int 2020; 20: 980-987.
Substances chimiques
Biomarkers
0
GDF15 protein, human
0
Growth Differentiation Factor 15
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
980-987Subventions
Organisme : National Center for Geriatrics and Gerontology
Informations de copyright
© 2020 Japan Geriatrics Society.
Références
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. European working group on sarcopenia in older people. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 2010; 39: 412-423.
Chen LK, Woo J, Assantachai P et al. Asian working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020; 21: 300-307.
Cruz-Jentoft AJ, Bahat G, Bauer J et al. Writing Group for the European Working Group on sarcopenia in older people 2 (EWGSOP2), and the extended group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16-31.
Beaudart C, Reginster JY, Petermans J et al. Quality of life and physical components linked to sarcopenia: the SarcoPhAge study. Exp Gerontol 2015; 69: 103-110.
Lee JS, Auyeung TW, Leung J, Kwok T, Leung PC, Woo J. The effect of diabetes mellitus on age-associated lean mass loss in 3153 older adults. Diabet Med 2010; 27: 1366-1371.
Park SW, Goodpaster BH, Strotmeyer ES et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 2006; 55: 1813-1818.
Wang CP, Hazuda HP. Better glycemic control is associated with maintenance of lower-extremity function over time in Mexican American and European American older adults with diabetes. Diabetes Care 2011; 34: 268-273.
Bootcov MR, Bauskin AR, Valenzuela SM et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997; 94: 11514-11519.
Adela R, Banerjee SK. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res 2015; 2015: 490842.
Fujita Y, Ito M, Kojima T, Yatsuga S, Koga Y, Tanaka M. GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. Mitochondrion 2015; 20: 34-42.
Yatsuga S, Fujita Y, Ishii A et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol 2015; 78: 814-823.
Ito T, Nakanishi Y, Yamaji N, Murakami S, Schaffer SW. Induction of growth differentiation factor 15 in skeletal muscle of old Taurine transporter knockout mouse. Biol Pharm Bull 2018; 41: 435-439.
Chung HK, Ryu D, Kim KS et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J Cell Biol 2017; 216: 149-165.
Fujita Y, Taniguchi Y, Shinkai S, Tanaka M, Ito M. Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatr Gerontol Int 2016; 16 (Suppl 1): 17-29.
Umegaki H. Sarcopenia and frailty in older patients with diabetes mellitus. Geriatr Gerontol Int 2016; 16: 293-299.
Tamura Y, Ishikawa J, Fujiwara Y et al. Prevalence of frailty, cognitive impairment, and sarcopenia in outpatients with cardiometabolic disease in a frailty clinic. BMC Geriatr 2018; 18: 264.
Matsuo S, Imai E, Horio M et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
Scherbakov N, Knops M, Ebner N et al. Evaluation of C-terminal Agrin fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation. J Cachexia Sarcopenia Muscle 2016; 7: 60-67.
Varlet-Marie E, Joré C, Brun JF. Segmental bioelectrical impedance analysis (SBIA) and blood rheology: reducing the gap between in vivo and in vitro? Clin Hemorheol Microcirc 2016; 64: 603-611.
Nordin E, Lindelöf N, Rosendahl E, Jensen J, Lundin-Olsson L. Prognostic validity of the timed up-and-go test, a modified get-up-and-go test, staff's global judgement and fall history in evaluating fall risk in residential care facilities. Age Ageing 2008; 37: 442-448.
Abe T, Tsuji T, Soma Y, Shen S, Okura T. Composite variable of lower extremity muscle strength and balance ability for evaluating risks of mobility limitation and falls in community-dwelling older adults. J Phys Fit Sports Med 2016; 5: 257-266.
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
Gerstein HC, Pare G, Hess S et al. Growth differentiation factor 15 as a novel biomarker for metformin. Diabetes Care 2017; 40: 280-283.
Semba RD, Gonzalez-Freire M, Tanaka T et al. Elevated plasma growth and differentiation factor 15 is associated with slower gait speed and lower physical performance in healthy community-dwelling adults. J Gerontol A Biol Sci Med Sci 2020; 75: 175-180.
Patel MS, Lee J, Baz M et al. Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo. J Cachexia Sarcopenia Muscle 2016; 7: 436-448.
Li M, Song K, Huang X, Fu S, Zeng Q. GDF-15 prevents LPS and D-galactosamine-induced inflammation and acute liver injury in mice. Int J Mol Med 2018; 42: 1756-1764.
Tang H, Inoki K, Brooks SV et al. mTORC1 underlies age-related muscle fiber damage and loss by inducing oxidative stress and catabolism. Aging Cell 2019; 18: e12943.
Abrigo J, Simon F, Cabrera D, Vilos C, Cabello-Verrugio C. Mitochondrial dysfunction in skeletal muscle pathologies. Curr Protein Pept Sci 2019; 20: 536-546.
Mullican SE, Lin-Schmidt X, Chin CN et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 2017; 23: 1150-1157.
Landi F, Liperoti R, Russo A et al. Association of anorexia with sarcopenia in a community-dwelling elderly population: results from the ilSIRENTE study. Eur J Nutr 2013; 52: 1261-1268.
Schaap LA, Pluijm SM, Deeg DJ et al. Health ABC study. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 2009; 64: 1183-1189.
Hong JH, Chung HK, Park HY et al. GDF15 is a novel biomarker for impaired fasting glucose. Diabetes Metab J 2014; 38: 472-479.
Shin MY, Kim JM, Kang YE et al. Association between growth differentiation factor 15 (GDF15) and cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus. J Korean Med Sci 2016; 31: 1413-1418.
Coll AP, Chen M, Taskar P et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature 2020; 578: 444-448.